Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis

Yzabella Alves Campos Nogueira1, Loredana Nilkenes Gomes da Costa1,2, Carlos Emilio Levy1

  • 1School of Medical Sciences, University of Campinas, Campinas, SP, Brazil.

Plos One
|January 1, 2020
PubMed

Insights

Tranexamic acid (TnxAc), an antifibrinolytic, did not improve survival or reduce injury in a sepsis model. This study suggests TnxAc is not beneficial for sepsis and addresses its thrombotic safety in this context.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Hematology

Background:

  • Fibrinolysis plays a role in the host response to sepsis, with pathogens challenging the host's pro- and anti-fibrinolytic balance.
  • Early sepsis stages often show hypofibrinolysis, but its benefit or detriment to the host remains debated.
  • Tranexamic acid (TnxAc), an antifibrinolytic, is used for bleeding but sepsis often follows procedures where it's administered.

Purpose of the Study:

  • To investigate the impact of TnxAc-induced hypofibrinolysis on survival, tissue injury, and pathogen spread in a polymicrobial sepsis model.
  • To assess the potential benefits or risks of using TnxAc in sepsis.
  • To contribute data on the interplay between fibrinolysis and innate immunity.

Main Methods:

  • A polymicrobial sepsis model was established in mice using cecal ligation and puncture.
  • Mice received two doses of TnxAc twice daily for 48 hours before sepsis induction.
  • Survival, tissue injury (biochemical and histological), cytokine levels, and pathogen spread were evaluated.

Main Results:

  • TnxAc successfully induced hypofibrinolysis in the sepsis model.
  • No significant differences were observed in survival rates between TnxAc-treated and control groups.
  • Tissue injury, cytokine levels, and pathogen spread remained unchanged by TnxAc treatment.

Conclusions:

  • TnxAc-induced hypofibrinolysis did not improve outcomes in this polymicrobial sepsis model.
  • The findings do not support the use of TnxAc for treating sepsis.
  • The study provides data on the thrombotic safety of TnxAc, a widely used antifibrinolytic agent.

Related Concept Videos